Redeye raises Medicover's fair value per share to SEK 205. We expect a strong recovery of electable procedures in Medicover's hospitals and clinics during 2021 and beyond, and strong growth in the diagnostics division. Medicover is a well-managed business, with a good balance sheet, on a path to consistent earnings growth.